Who is sponsoring NCT03737669?

NCT03737669 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT03737669?

Interventions in NCT03737669: Mirasol-treated Fresh Whole Blood, Standard Fresh Whole Blood.

What condition does NCT03737669 study?

NCT03737669 studies Transfusion-Transmitted Infectious Disease.

Is NCT03737669 still recruiting?

NCT03737669 is currently completed. Last updated 6 October 2025.

Last reviewed 2025-10-06 · How we verify

NCT03737669: MERIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mirasol Evaluation of Reduction in Infections Trial

Completed Phase 3 Last updated 6 October 2025

What this trial tests

Phase 3 trial testing Mirasol-treated Fresh Whole Blood in Transfusion-Transmitted Infectious Disease in 2,000 participants. Completed in 29 September 2025.

Timeline

13 November 2019

Primary endpoint
29 September 2025

29 September 2025

Quick facts

Lead sponsor	Johns Hopkins University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	2,000
Start date	13 November 2019
Primary completion	29 September 2025
Estimated completion	29 September 2025
Sites	1 location across Uganda

Drugs / interventions tested

Mirasol-treated Fresh Whole Blood — full drug profile →
Standard Fresh Whole Blood — full drug profile →

Conditions studied

Transfusion-Transmitted Infectious Disease — all drugs for Transfusion-Transmitted Infectious Disease →

Sponsor

Johns Hopkins University

Who can join

Eligibility, any sex, with Transfusion-Transmitted Infectious Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized, double-blind, controlled study to determine the effectiveness of Mirasol-treated fresh whole blood (FWB) versus Standard-issue FWB for preventing transmission of transfusion-transmitted infections (TTIs). The incidence of pre-defined viral, bacterial, or parasitic TTIs in previously negative participants will be assessed by changes in laboratory findings at multiple time points over the course of the clinical trial.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial.
Kasirye R, Hume HA, Bloch EM, Lubega I, et al · · 2022 · cited 13× · PMID 35379302 · DOI 10.1186/s13063-022-06137-8
Kaposi's sarcoma herpesvirus seroprevalence among blood donors in Uganda.
Huso T, White JL, Kyeyune D, D'Adamo A, et al · · 2025 · cited 1× · PMID 40172229 · DOI 10.1111/trf.18236
Pathogen inactivation of red cell concentrates and whole blood: II. In vivo human recovery studies, clinical trials and future directions.
van der Meer PF, Cancelas JA, Klei TRL. · · 2026 · PMID 41158006 · DOI 10.1111/vox.70132

Verify or expand the search:

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03737669 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 6 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03737669.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing